Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib

Lee Min Kyung; Kwon Won Joo; Cho Eun Byul; Park Eun Joo; Kim Kwang Ho; Kim Kwang Joong

首页> 外文期刊>Annals of Dermatology >Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib

【24h】

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib

机译：甲磺酸伊马替尼诱导的多形性红斑：再用200毫克/天的伊马替尼挑战后复发

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of Dermatology》 |2015年第5期|共3页
作者
Lee Min Kyung; Kwon Won Joo; Cho Eun Byul; Park Eun Joo; Kim Kwang Ho; Kim Kwang Joong;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献
中文文献
专利

1. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib [J] . Bruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, Therapeutic advances in medical oncology. . 2018,第3期

机译：用伊马替尼，舒尼替尼和雷戈非尼治疗后进展期胃肠道间质瘤患者接受伊马替尼再挑战
2. Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib [J] . AkiraSawaki, TatsuoKanda, YoshitoKomatsu, Gastroenterology research and practice . 2014,第1期

机译：伊马替尼和舒尼替尼治疗失败对晚期胃肠道间质瘤患者进行再挑战的影响
3. Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors [J] . Monia Savi, Caterina Frati, Stefano Cavalli, Pharmacological research: The official journal of The Italian Pharmacological Society . 2018,第期

机译：伊马替尼甲磺酸盐诱导的心肌病包括常规心脏祖细胞
4. Combination Effects of Gambogic Acid on Imatinib Mesylate Cytotoxicity in Colon Cancer Cells [C] . El Mon Khaing, THANIKA Saenpunya, PITTAWAS Kerdklai International conference and exhibition on Pharmaceutical Sciences and Technology . 2020

机译：甘伐酸对伊马替尼甲磺酸盐细胞毒性在结肠癌细胞中的组合作用
5. Targeting Chronic Myelogenous Leukemia with IMATINIB and Glycyrrhizic Acid Combination Therapy [D] . Mohaban, Adir. 2022

机译：用伊马替尼和甘草组合治疗靶向慢性髓性白血病
6. Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib [O] . Min Kyung Lee, Won Joo Kwon, Eun Byul Cho, 2015

机译：甲磺酸伊马替尼诱导的多形性红斑：以200毫克/天的伊马替尼挑战后复发
7. 140Safety, tolerability and drug interactions of adjuvant imatinib mesylate (GLEEVEC®) within the first 100 days following stem cell transplantation (SCT) in patients with PH+ CML and PH+ all at high risk for recurrence [O] . Sheth S.R., Hicks K., Ippoliti C., 2003

机译：140对具有高复发风险的PH + CML和PH +患者的干细胞移植（SCT）后头100天内甲磺酸伊马替尼辅助药物（GLEEVEC®）的安全性，耐受性和药物相互作用

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib

著录项

相似文献

相关主题

期刊订阅